Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dendritic cell vaccine - Medigene

Next Previous
Search
Drug Profile

Dendritic cell vaccine - Medigene

Alternative Names: CVT-DC-01; DC vaccine - Medigene Immunotherapies; IL-12p70 DC vaccine; Leukemia-associated RNA transfected autologous dendritic cell vaccine - Medigene Immunotherapies; PRAME-mRNA-transfected dendritic cell vaccines - Medigene Immunotherapies; TLR-7/8-polarised dendritic cell vaccines - Medigene Immunotherapies; WT1-mRNA-transfected dendritic cell vaccines - Medigene Immunotherapies

Latest Information Update: 08 Aug 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trianta Immunotherapies
  • Developer Ludwig-Maximilians-University; Medigene Immunotherapies; University of Oslo
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Prostate cancer

Most Recent Events

  • 31 Jul 2022 Hongsheng Sciences (formerly Cytovant) temporarily suspended its Medigene partnership development activity due to financing constraints
  • 25 Jul 2022 The University of Oslo completes the phase I/II trial in Prostate cancer in Norway (EudraCT2010-018770-20, NCT01197625)
  • 08 Feb 2021 Efficacy data from phase I/II trial in Myeloid leukaemia released by Medigen AG

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top